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THE FUTURE OF BIOTECHNOLOGY: ACCELERATING
GENE-EDITING ADVANCMENETS THROUGH NONEXCLUSIVE LICENSES AND OPEN-SOURCE ACCESS OF
CRISPR-CAS9.
By Emily N. Rissberger1
From the immune system of bacteria comes a promising new geneediting technology, CRISPR-Cas9. Discovered in 2012, CRISPR-Cas9
has already been named one of the fastest, easiest, and cheapest geneediting technologies. With this reputation, CRISPR-Cas9 shows
promise in the research and treatments of a wide array of diseases.
Cancer, blood disorders, blindness, AIDS, Cystic Fibrosis, Muscular
Dystrophy, Huntington’s disease, and even COVID-19 to name a few.
This relatively new technology has brought hope to researchers,
doctors, and patients alike. However, current biotechnology licensing
practices could hinder CRISPR-Cas9’s groundbreaking potential.
This article examines common biotechnology licensing practices,
specifically the practices of two of the largest CRISPR-Cas9 patent
holders, The University of Berkeley and The Broad Institute of MIT
and Harvard. After each institution’s respective CRISPR-Cas9
discovery the two battled it out to determine which institution
discovered CRIPR-Cas9 first and whether patent infringement existed.
Eventually, both institutions were granted their desired patents and
quickly ensured the future of their technologies, created independent
companies to control the licensing of CRISPR-Cas9 patents. This
article refers to such companies as “surrogate companies” and
explains the function of these entities as the gatekeeper of valuable
patent rights through overinclusive exclusive licenses.
This article offers solutions to existing exclusive licenses without
losing sight of the important relationship between research institutions
and surrogate companies. Providing limited field of use licenses,
rather than overinclusive exclusive licenses, of CRISPR-Cas9 patented
technology will ensure a wider range of the human genome be
discovered. Limited licenses allow companies to focus on specific
goals, reducing the possibility of a gene therapy being overlooked and
underdeveloped. This article goes further, suggesting the
biotechnology industry adopt an open-source access model like the one
used in the software industry. Such a model could prove beneficial for
1
Tech Edge JD Candidate, Santa Clara University School of Law, 2022. The
author thanks her friends and family for their unwavering support and
guidance through the research and writing process and the editors of the Santa
Clara High Technology Law Journal for their helpful edits.
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companies looking to expand product offerings while still maintaining
profits. Historically low-profit diseases like tropical diseases could
become more desirable to companies based on collaboration and
reduced R&D costs from employing open-source practices.
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INTRODUCTION
The ability to modify genes “easily and efficiently . . . holds
immense promise to transform basic science, biotechnology, and
medicine.”2 CRISPR-Cas9 is one of the promising technologies in
gene editing. With promising results in sickle cell disease trials and
opportunities to treat genetic diseases such as cystic fibrosis and
muscular dystrophy, CRISPR-Cas9 is the future of medicine.3
Unfortunately, the potential of this revolutionary technology is
dwindling, with CRISPR-Cas9 patent owners putting profits over
accessibility and broad application.
The biotechnology industry provides hope for the future of
disease management and treatments. However, the industry is
currently riddled with patent thickets (multiple over-inclusive patents
covering the same area of technology), over-inclusive licenses, and a
profit over progress mindset that currently inhibits the industry’s
revolutionary potential. As a relatively new industry, biotechnology
can take inspiration from the software industry’s open-source model,
providing public access to research and encouraging collaboration to
create the future of biotechnology.
I.

AN INTRODUCTION TO GENE EDITING

Genome-editing (gene-editing) is a group of technologies that
allow genetic material to be altered.4 Editing occurs at a particular
location in the genome that allows scientists to change an organism's
DNA.5 Gene-editing has been used to genetically modify crops to
improve yields, prevent disease, and survive droughts.6 Crops that
have undergone such editing are genetically modified organisms or
GMOs.7 Gene-editing is also used to research and treat diseases
1

Patrick D. Hsu, Eric S. Lander, Feng Zhang, Development and Applications
of CRISPR-Cas9 for Genome Engineering, CELL, 1262, 1263 (June 5, 2014).
3
Emily Mullin, Fresh Off Her Nobel Prize Win, Jennifer Doudna Predicts
What’s Next for CRISPR, Future Human (Oct. 12, 2020),
https://futurehuman.medium.com/fresh-off-her-nobel-prize-win-jenniferdoudna-predicts-whats-next-for-crispr-1fea0225c41d.
4
What are genome editing and CRISPR-Cas9?, U.S. NATIONAL LIBRARY OF
MEDICINE
(June
23,
2020),
https://medlineplus.gov/genetics/understanding/genomicresearch/genomeedi
ting/.
5
Id.
6
What is genome editing?, yourgenome (Aug. 23, 2017),
https://www.yourgenome.org/facts/what-is-genome-editing.
7
What
is
a
GMO?,
yourgenome
(Feb.
17,
2017),
https://www.yourgenome.org/facts/what-is-a-gmo.
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currently “being explored in research on a wide variety of diseases,
including single-gene disorders such as cystic fibrosis, hemophilia, and
sickle cell disease . . . and more complex diseases such as cancer and
AIDS.”8
A. How Gene-Editing Works
On a basic level, gene-editing is the process of slicing and
dicing genetic material to change the structure of targeted DNA.9 More
specifically, an enzyme referred to as an “engineered nuclease” cuts a
genome in a specific location.10 After being cut, the cell naturally
repairs itself.11 This repair process is where the “editing” occurs.12
During the repair process, some of the DNA may be lost or added
around the site of the cut.13 These deletions or additions affect the
function of the DNA.14 To remove DNA, an engineered nuclease cuts
either side of the section to be removed.15 To repair this cut, the DNA
recognizes the damage done and joins the ends of the two cuts
together.16 To insert a new section of DNA, an engineered nuclease
cuts a specific location and introduces a modified piece of the
previously cut DNA into the location. 17 The cell uses this modified
piece to fill in the cut section.18
II.

CRISPER-CAS9:
TECHNOLOGY

A

REVOLUTIONARY

GENE

EDITING

There are several kinds of engineered nucleases used in geneediting. One of the most commonly used engineered nucleus is
CRISPR-Cas9, originally discovered in bacteria that use CRISPRCas9 to destroy invading viruses.19 CRISPR stands for “clustered
8

What are genome editing and CRISPR-Cas9?, supra note 3.
What is genome editing?, supra note 5.
10
Id.
11
Id.
12
Id.
13
Id.
14
What is genome editing?, supra note 5.
15
Id.
16
Id.
17
What is genome editing?, supra note 5.
18
Id.
19
Thomas Gaj, Shannon J. Sirk, Sai-Ian Shui, & Jia Liu, Genome-Editing
Technologies: Principles and Applications, Cold Spring Hard Perspect Biol,
(Dec. 2016), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131771/. See
also, University of Zurich. New Bacterial Defense Mechanism of the CRISPRCas
System
Uncovered,
ScienceDaily
(July
18,
2017),
https://www.sciencedaily.com/releases/2017/07/170718113722.htm.
9
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regularly interspaced short palindromic repeats,”20 and Cas9 represents
CRISPR-associated protein 9.21 CRISPR can be accompanied by other
Cas proteins such as Cas12, Cas14, CasX, and CasY.22 However, this
article’s main focus is on CRISPR-Cas9 and will stick to referring only
to the Cas9 protein system. To utilize CRISPR-Cas9, researchers
create a guide sequence of RNA which is attached to the DNA
sequence being edited.23 The guide RNA shows the Cas9 protein where
to cut the DNA, and the Cas9 protein proceeds with the cut. 24 Once
cut, researchers manipulate the cell’s DNA repair mechanism to either
add or delete genetic material.25 Researchers can also change DNA by
“replacing an existing segment with a customized DNA sequence.”26
A. CRISPR-Cas9 in Use
CRISPR-Cas9 can be used either by editing cells that have
been removed from the body or injecting the gene-editing system
directly into the body.27 The latter process has been used in a clinical
trial to treat Leber’s Congenital Amaurosis (LCA10), a rare cellular
mutation that disables light-sensing cells in the retina.28 LCA10 is also

20

What are genome editing and CRISPR-Cas9?, supra note 3.
Heidi Ledford & Ewen Callaway, Pioneers of Revolutionary CRISPR Gene
Editing
Win
Chemistry
Nobel,
Nature
(Oct.
7,
2020),
https://www.nature.com/articles/d41586-020-02765-9.
22
Fiona Mischel, Who Owns CRISPR in 2021? It’s Even More Complicated
Than You Think, Synbiobeta (Apr. 27, 2021), https://synbiobeta.com/whoowns-crispr-in-2021-its-even-more-complicated-than-you-think/.
23
Id.
24
Id.
25
Id.
26
What are genome editing and CRISPR-Cas9?, supra note 3.
27
See Rob Stein, In A 1st, Scientists Use Revolutionary Gene-Editing Tool To
Edit
Inside
A
Patient,
NPR
(Mar.
4,
2020),
https://www.npr.org/sections/health-shots/2020/03/04/811461486/in-a-1stscientists-use-revolutionary-gene-editing-tool-to-edit-inside-a-patient. See
also Rob Stein, He Inherited A Devastating Disease. A CRISPR Gene-Editing
Breakthrough
Stopped
It,
NPR
(June
26,
2021),
https://www.npr.org/sections/health-shots/2021/06/26/1009817539/heinherited-a-devastating-disease-a-crispr-gene-editing-breakthrough-stoppedit.
28
Rob Stein, In A 1st, Scientists Use Revolutionary Gene-Editing Tool To Edit
Inside A Patient, NPR (Mar. 4, 2020), https://www.npr.org/sections/healthshots/2020/03/04/811461486/in-a-1st-scientists-use-revolutionary-geneediting-tool-to-edit-inside-a-patient.
21
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one of the most common causes of childhood blindness.29 Microscopic
droplets carrying the CRISPR-Cas9 gene-editing system were injected
into the patient’s eye in hopes of repairing the gene mutation.30 This
procedure demonstrates CRISPR-Cas9’s ability to “open entire[ly]
new areas of medicine and lead to a whole new class of therapies for
diseases that are not treatable any other way.”31
Currently, “one of the biggest challenges with applying
CRISPR clinically so far, [] is being able to deliver it systemically and
get it to the right place.”32 In June of 2021, early data indicated direct
injection of CRISPR-Cas9 into a patient’s bloodstream was a
success.33 CRISPR-Cas9 was injected directly into the bloodstream of
patients with transthyretin amyloidosis, a rare inherited disease that
produces misshapen proteins that attack important tissues and nerves.34
Amyloidosis deteriorates the body, eventually leading to death.35 The
amyloidosis treatment is the first instance of CRISPR-Cas9 being
injected directly into a patient’s bloodstream.36 The injection of
CRISPR-Cas9 into the bloodstream significantly reduced the levels of
destructive proteins in patients.37 Injecting directly into a patient
bloodstream could help overcome CRISPR-Cas9’s delivery
challenges, opening the door to further treatment of diseases that affect
tissue not located near possible injection sites.38
B. The Institutions Behind Discovering CRISPR-Cas9
The CRISPR-Cas9 engineered nuclease is “faster, cheaper,
more accurate, and more efficient than other existing genome editing
methods.”39 CRISPR-Cas9 has the potential to transform the way
scientists study disease and the human genome. This makes it a highly
29

Bill Holton, Vision Tech: Several Gene Therapies for Blindness Reach
Clinical Trials, American Foundation for the Blind, (Nov. 2019),
https://www.afb.org/aw/20/11/16815.
30
Id.
31
Id. (alteration in original).
32
Rob Stein, He Inherited A Devastating Disease. A CRISPR Gene-Editing
Breakthrough
Stopped
It,
NPR
(June
26,
2021),
https://www.npr.org/sections/health-shots/2021/06/26/1009817539/heinherited-a-devastating-disease-a-crispr-gene-editing-breakthrough-stoppedit.
33
Id.
34
Stein, He Inherited, supra note 31.
35
Id.
36
Id.
37
Id.
38
Id.
39
What are genome editing and CRISPR-Cas9?, supra note 3.
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desirable technology that has been mired with intellectual property
(“IP”) rights disputes.40 UC Berkeley and the Broad Institute of MIT
and Harvard (hereinafter “Broad” or “Broad Institute”) are the main
contenders in the fight for CRISPR-Cas9 IP rights.41 Both parties claim
the IP rights to CRISPR-Cas9 technology.
In 2012, Berkeley Professor of Chemistry, Jennifer Doudna,
and her team developed the CRISPR-Cas9 technology,42 applying to
patent their discovery with the USPTO in May of the same year.43 At
the same time, a team at the Broad Institute was researching human
gene-editing CRISPR technology.44 The Broad Institute team’s first
application of CRISPR-Cas9 in eukaryotic cells used a guide that
combined two RNA molecules, while the UC Berkeley team’s
CRISPR relied on a single RNA rather than two to accomplish the
same result.45 This single-molecule guide RNA is now the standard
tool in the field.46
The Broad Institute team filed a patent for its CRISPR
technology in December of 2012.47 Although the UC Berkeley team
had applied seven months prior, the Broad Institute team was awarded
its CRISPR patent48 first because the Broad Institute paid to expedite
their application.49 As of 2013, the USPTO has operated under a firstto-file system.50 This system would have alleviated the resulting legal
battle between UC Berkeley and the Broad Institute.51
Consequently, in 2016 the UC Berkeley team requested that
the U.S. Patent Trial and Appeal Board (PTAB) begin an interference
proceeding to determine which team was entitled to CRISPR-Cas9
rights.52 These proceedings found no interference between the
40

Mischel, supra note 21.
Id.
42
Mark Summerfield, Who Will Get the CRISPR Patent?, Patentology (Jan.
17, 2016), https://blog.patentology.com.au/2016/01/who-will-get-crisprpatent.html.
43
U.S. Patent No. 10,266,850 (issued Apr. 23, 2019).
44
Jon Cohen, The Latest Round in the CRISPR Patent Battle has an Apparent
Victor, but the Fight Continues, ScienceMag (Sept. 11, 2020),
https://www.sciencemag.org/news/2020/09/latest-round-crispr-patent-battlehas-apparent-victor-fight-continues.
45
Id.
46
Id.
47
Summerfield, supra note 41.
48
U.S. Patent No. 8,697,359 (issued Apr. 15, 2014).
49
Summerfield, supra note 41.
50
Id.
51
Mischel, supra note 21.
52
Summerfield, supra note 41.
41
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CRISPR-Cas9 patents for gene and animal cells held by the Broad
Institute and the patent application for gene editing in all environments
filed by UC Berkeley.53 In 2018, a Federal Circuit affirmed the U.S.
Patent Board’s finding54 allowing the Broad Institute to “maintain its
extensive CRISPR patent portfolio.”55 This decision did not
interfere with UC Berkeley’s patent application which was
eventually granted. 56
Recently in September of 2020, the PTAB ruled that “the
Broad Institute has ‘priority’ in its already granted patents for uses of
the original CRISPR system in eukaryotic cells.”57 Such a patent
covers potentially lucrative applications in humans and lab-grown
human cells.58 However, UC Berkeley is still hopeful that the ruling
will lead to the “PTAB [ ] recogniz[ing] that the [UC Berkeley] team
was first to invent the CRISPR-Cas9 technology in eukaryotic cells.”59
The European Patent Office (“EPO”) has added complexity to
the already complex CRISPR-Cas9 patent battle. In 2012, the EPO
favored UC Berkeley, granting the university its CRISPR-Cas9 patents
before Broad due to a technical issue on Broad’s application. 60
However, more recently in 2021, the EPO has revoked two of UC
Berkley’s CRISPR-Cas9 patents based on an invalid priority claim.61
Although this article focuses on the CRISPR-Cas9 battle in the United
States, these EPO decisions provide insight into the ever-changing
gene-editing patent landscape. This article focuses on United States
53

Public Affairs, UC Files Appeal to Revive CRISPR Patent Interference,
Berkeley News (July 26, 2017), https://news.berkeley.edu/2017/07/26/ucfiles-appeal-to-revive-crispr-patent-interference/.
54
Regents of Univ. of California v. Broad Inst., Inc., 903 F.3d 1286, 1296-97
(Fed. Cir. 2018).
55
Kevin Noonan, Federal Circuit Affirms PTAB in Appeal of CRISPR
Interference,
JDSupra.com,
(Sep.
11,
2018),
https://www.jdsupra.com/legalnews/regents-of-the-university-of-california52116/.
56
Id.
57
Cohen, supra note 43.
58
Id.
59
Id.
60
Vincent M. Grandpré & Felicia Lozon, Making Sense of the Battle for the
CRISPR-Cas9
Patent
Rights,
Osler
(Mar.
15,
2021),
https://www.osler.com/en/resources/critical-situations/2021/making-senseof-the-battle-for-the-crispr-cas9-patent-rights.
61
Chrisitane G. Espino & Fangli Chen, UC Berkeley CRISPR Patent Revoked
in Europe Due To Invalid Priority Claim, 11 Nat’l L. Rev. (May 24, 2021),
https://www.natlawreview.com/article/uc-berkeley-crispr-patent-revokedeurope-due-to-invalid-priority-claim.
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patent law in analyzing the current CRISPR-Cas9 landscape. However,
the above information on the EPO shows the complexity of this
revolutionary technology and the potential ownership issues that can
arise when research is conducted globally.
C. The Extensive CRISPR-Cas9 Patent Portfolios of UC
Berkeley and Broad Institute of MIT and Harvard
Despite the ongoing patent dispute between UC Berkeley and
Broad Institute, both institutions have managed to accumulate large
CRISPR-Cas9 patent portfolios. With both UC Berkeley and Broad
Institute holding CRISPR patents “a third party wishing to utilize the
technology in eukaryotic cells (encompassing everything from yeast
to man) would need a license from both the University [of California
Berkeley] and Broad [Institute].”62 Multiple companies have been
founded on UC Berkeley and Broad’s initial CRISPR IP rights,
specifically Caribou Biosciences (UC Berkeley) and Editas Medicine
(Broad).63 These “for-profit surrogate companies”64 act as the patent
owner, functioning as the “gatekeepers” to the CRISPR-Cas9 geneediting industry.65 The surrogate model allows universities and
institutions to maximize profits while minimizing licensing risks.66
With a surrogate company dealing with licensing, universities and
institutions are free to focus on research and development to expand
their patentable technologies further.67
Currently, UC Berkeley holds the United States’ largest
CRISPR-Cas9 patent portfolio,68 gaining 18 CRISPR-Cas9 related
patents in 2019.69 As of May 2021, UC Berkeley owns 44 CRISPR-

62

Noonan, supra note 54.
Mischel, supra note 21.
64
Lisa M. Krieger, How UC-Berkeley’s CRISPR License Could Limit
Innovation,
The
Mercury
News
(Feb.
16,
2017),
https://www.mercurynews.com/2017/02/16/how-uc-berkeleys-crisprlicense-could-limit-innovation/.
65
Jorge L. Contreras & Jacob S. Sherkow, CRISPR, Surrogate Licensing, and
Scientific Discovery, 355 SCIENCE 698, 698 (2017).
66
Id.
67
Id.
68
Public Affairs, UC Now Holds Largest CRISPR-Cas9 Patent Portfolio,
Berkeley News (Oct. 1, 2019), https://news.berkeley.edu/2019/10/01/ucnow-holds-largest-crispr-cas9-patent-portfolio/.
69
Robert Sanders, UC Rings Out 2019 with its 20th CRISPR Patent, Berkeley
News (Dec 31, 2019), https://news.berkeley.edu/2019/12/31/uc-rings-out2019-with-its-20th-crispr-patent/.
63
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based patents in the United States.70 This collection of patents can
be used by nonprofits and academic institutions for non-commercial
research and educational purposes as part of UC Berkeley’s openlicensing policy.71 Commercial use of these patents is exclusively
licensed to Caribou Biosciences (“Caribou”).72 Caribou sublicenses
UC Berkeley’s CRISPR patents to “strategic partners who are
“recognized leaders in many market sectors.”73 One such partner is
Intellia Therapeutics Inc., another UC Berkeley surrogate company
created for CRISPR-Cas9 application in human therapeutic.74
Similar to UC Berkeley, Broad Institute also requires an
exclusive license to use its CRISPR IP for human therapeutic
research and development.75 Broad Institute only waives the need for
a written license for institutions looking to use its CRISPR-Cas9 IP
for academic and non-profit research.76 Under its “inclusive
innovation” model, an alternative term for the exclusive license
model, Broad Institute licenses its CRISPR-Cas9 technology to a
primary licensee.77 After a specified time, non-competitors of the
primary licensee may apply for a CRISPR-Cas9 license by
presenting Broad Institute with a development plan.78 This
development plan explains how the company will use Broad
Institute’s CRISPR IP.79
The primary licensee has access to this development plan to
ensure the plan does not infringe on the primary licensee’s exclusive

70
Robert Sanders, UC Berkeley Will Auction NFTs of Nobel Prize-Winning
Inventions to Fund Research, Berkeley News (May 27, 2021),
https://news.berkeley.edu/2021/05/27/uc-berkeley-will-auction-nfts-ofnobel-prize-winning-inventions-to-fund-research/.
71
Public Affairs, CRISPR portfolio now at 14 and counting, Berkley Research
(Sep. 17, 2019), https://vcresearch.berkeley.edu/news/crispr-portfolio-now14-and-counting.
72
Public Affairs, UC Now Holds Largest CRISPR-Cas9 Patent Portfolio,
Berkeley News (Oct. 1, 2019), https://news.berkeley.edu/2019/10/01/ucnow-holds-largest-crispr-cas9-patent-portfolio/.
73
Licences, Caribou Biosciences, https://cariboubio.com/#licenses.
74
Sanders, UC Rings, supra note 68.
75
Information About Licensing CRISPR Systems, Including for Clinical Use,
Broad Inst., available at https://www.broadinstitute.org/partnerships/officestrategic-alliances-and-partnering/information-about-licensing-crisprgenome-edi (last visited Sept. 10, 2021).
76
Id.
77
Information About Licensing CRISPR Systems, supra note 74.
78
Id.
79
Id.
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CRISPR-Cas9 license.80 If a primary licensee has plans to apply
CRISPR-Cas9 to the same genes or diseases as its noncompetitor
who submitted a development plan, then the non-competitor
becomes a competitor and cannot obtain a CRISPR license.81 This
model “enable[s] the primary licensee to devote sufficient investment
to develop CRISPR-based genome editing technology to treat human
diseases, while supporting broad development of medicines to reach
many patients.”82
Both UC Berkeley and Broad Institute’s licensing schemes risk
excluding innovative companies from accessing CRISPR-Cas9
technology. With an exclusive license over UC Berkeley’s vast
CRISPR-Cas9 patent collection, Caribou has the discretion to choose
which companies can sublicense and use UC Berkeley’s revolutionary
technology. Broad Institute’s “inclusive innovation” licensing model,
in practice, does not support the broad development of medicines. This
model gives its primary licensee, Editas Medicine, run by “Feng Zhang
of the Broad Institute of MIT and Harvard,”83 close to exclusive control
over the CRISPR industry. UC Berkeley and Broad Institute’s
licensing practices make it difficult for companies not affiliated with
UC Berkeley or Broad Institute to enter the CRISPR market.
III.

EXCLUSIVE
INDUSTRY

LICENSING

AND

THE

BIOTECHNOLOGY

The exclusive licensing schemes used by UC Berkeley and
Broad Institute diminish the incentive for the academic community to
research CRISPR-Cas9 application in gene-editing. Although
academic and non-profit use of both institutes’ patents is allowed, the
researchers and academics who use these patents “don’t have the right
to market and sell products derived from their research.”84 An
additional roadblock to CRISPR-Cas9 access is surrogate company
approval requirements. The exclusive licenses granted to UC Berkeley
and Broad Institute’s respective surrogate companies prohibit
academic and nonprofit use of CRISPR-Cas9 for human therapeutics
and treatment without the approval of the exclusive licensee.85 The
surrogate model also disadvantages the patent owners, restricting UC
80

Id.
Id.
82
Id.
83
Sharon Begley, Exclusive CRISPR Licenses Slow Development of
Therapies, Legal Experts Argue,
STAT (Feb. 16, 2017),
https://www.statnews.com/2017/02/16/crispr-exclusive-licenses/.
84
Krieger, supra note 63.
85
Contreras & Sherkow, supra note 64, at 698.
81
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Berkeley and Broad Institute’s ability to grant similar licenses to other
companies without approval from their respective surrogate
companies.86
A. Congress’ Push to Make Federally Funded Research
Accessible and the Exclusive Licensing That Followed
Before 1980, open science prevailed in biotechnology, with
researchers “more inclined to share scientific findings rather than
shroud them in secrecy.”87 Some researchers from the 20th century
biomedical community even viewed patenting biomedical discoveries
as unethical.88 The social norms in the scientific community during this
time were rooted in communalism which discouraged claiming
property rights over inventions and keeping discoveries secret.89
Unfortunately, in a bid to “encourage the development of
commercializ[ing] products”, the United States Congress enacted the
Bayh-Dole Act in 1980 along with several other pro-patent right acts.90
These new laws allowed for the commercialization of publicly funded
research, replacing the scientific community’s communalism norm
with commercialization.91 The Bayh–Dole Act ushered in a new era of
federally funded research, allowing inventions created from federally
sponsored research to be owned by universities and institutions92 rather
than being assigned to the federal government.93
The act created a pathway to lucrative income by
commercializing university-developed technology.94 This new
revenue stream, which currently makes over $6 billion per year, led to
a rise in licensing activity among academic institutions.95 By creating
a uniform patent policy among federal agencies, the inventor
protections created by the Bayh-Dole Act incentivized universities and
86

Id. at 700.
Yann Joly, Open Source Approaches in Biotechnology: Utopia Revisited,
59 ME. L. REV. 385, 391 (2007).
88
Id.
89
Id.
90
Joly, supra note 86.
91
Id.
92
Vladimir Drozdoff & Daryl Fairbairn, Licensing Biotech Intellectual
Property in University–Industry Partnerships, COLD SPRING HARBOR
PERSPECT
MED.
1,
1
(2015),
available
at
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355252/.
93
Bayh-Dole Act: Regulations Impacting Ownership of Patent Rights,
University
of
Wisconsin-Madison
Research,
https://research.wisc.edu/bayhdole/ (last visited Sept. 23, 2021).
94
Id.
95
Drozdoff & Fairbairn, supra note 91 at 1.
87
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institutions to develop their research into lifesaving treatments.96 For
example, the Bayh-Dole Act made it possible for the University of
Michigan to create radioimmunotherapy, a treatment for a once
incurable form of follicular non-Hodgkin’s lymphoma, out of
Michigan’s pre-existing research.97 While the Bayh–Dole Act made
federal-funded research more accessible to taxpayers98, the era
following saw an increase in exclusive licensing schemes and
surrogate companies.
B. Exclusive Licensing Limits CRISPR-Cas9’s Potential
The large patent portfolios of both UC Berkeley and Broad are
at the root of the exclusive licensing problem. The overinclusive
patents used by these institutions create a patent thicket inhibiting the
further development of CRISPR-Cas9 technology and applications. A
patent thicket occurs when multiple patents state broader claims than
the actual invention discovered.99 When multiple patents cover the
same area of technology, as is the reality of the CRISPR patent
landscape, a thicket of existing patent rights develops.100 This thicket
requires potential developers to obtain rights from each patent holder
to minimize patent infringement liability.101
The exclusive licenses used by UC Berkeley and Broad
Institute further inhibit the full potential of CRISPR-Cas9 innovations,
holding back genome research and development. An exclusive license
is a contract that allows a licensee to exclusively exercise one or more
of a patent owners’ rights for a specific period.102 License agreements
are important to define the scope of rights being transferred and to lay
out the compensation for those rights.103 License agreements also
establish the risk each party takes on in carrying out the agreement.104
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Licensing rights, such as, exclusive licenses, are typically limit
by field of use restrictions.105 These restrictions inhibit a licensee’s
ability to exploit all fields of use of one technology, safeguarding
against one licensee controlling all preventive, diagnostic, and
therapeutic use for diseases in humans, animals, and plants.106
Although exclusive licenses are common in biotechnology, the
exclusive licenses granted to Caribou and Editas by their respective
founding institutions differ from the industry standard.
Instead of granting the exclusive use of one gene or a section
of a genome, the exclusive licenses UC Berkeley and Broad Institute
use cover “every gene in the human body and every gene known to
humankind.”107 One company is unlikely to research every aspect of
the human genome, meaning certain gene therapies could go
undeveloped or ignored.108 CRISPR-Cas9 patents and exclusive
licenses covering all known genes in both plant and animal cells create
an impossibility “for researchers to invent around”109 the patents
owned by UC Berkeley and Broad Institute.
Exclusive licenses covering the whole human genome restrict
the use of CRISPR technology to certain profitable genes selected by
surrogate companies and their sublicensees. This prevents CRISPRCas9 from being used to develop less profitable gene therapies,
hindering the technology’s full potential. Similar to for-profit
companies, surrogate companies focus on profitability when deciding
which genes to develop and which companies to grant sublicenses
to.110 Currently, within human therapeutics, surrogate companies are
focused on researching CRISPR-Cas9 effects on cancer, stem cells,
sickle cell anemia, and cystic fibrosis.111 These diseases make up only
a fraction of CRISPR-Cas9’s potential application in improving
genetic diseases. This for-profit model inhibits the development of less
profitable therapies, leaving the treatment of rare diseases or diseases
105
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that affect disadvantaged communities unresearched or worse,
undiscovered.112
Gene-editing industry members, such as Editas’ co-founder
George Church, believe exclusive licensees “have the potential to
impede research into therapeutic genome editing.”113 The monopoly of
therapeutic gene editing goes against the Patent and Trademark Law
Amendments Act, a federal regulation created in 1980 to “promote the
utilization of inventions arising from federally supported research or
development.”114 Through this act, the public can petition for patents
based on government-funded research to be licensed reasonably,
allowing the patent to be utilized to its full potential.115 The issue of
patent accessibility has reached the highest court in the land with the
Supreme Court of the United States, emphasizing the purpose of
patents, “which exist to promote creation.”116
The tragedy of the anticommons, first used by Heller and
Eisenberg in 1998, identifies the problem with over-inclusive
licensing.117 The tragedy of the anticommons is the idea that many
exclusive rights over a single resource will lead to the underutilization
of the resource.118 This tragedy perfectly describes the accessibility
issue created by UC Berkeley and Broad Institute’s CRISPR-Cas9
licensing scheme. Because of the over-inclusive licensing of CRISPRCas9 patents to surrogate companies, which in turn sublicense rights
to others, the use of CRISPR-Cas9 is limited to the most profitable
gene applications. This over fragmentation of patent rights deters
innovation and makes the application of less profitable genes unlikely
to be explored. Abandoning the surrogate exclusive license model is
realistic and can help UC Berkeley and Broad further develop the
CRISPR gene-editing industry. Non-exclusive licensing schemes have
been used by universities determined to promote innovation.119 Genesplicing patents issued to Stanford University in 1980 were never
exclusively licensed but still managed to promote innovation, leading
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to the creation and expansion of the biotechnology industry.120
Similarly, CRISPR technology has the potential to further advance the
biotechnology industry if the industry’s current exclusive licensing
practices are altered.
C. Alternatives to Exclusive Licenses.
In 2006, a set of points were drafted to help research
universities navigate the technology licensing of research tools. 121
Over 100 universities worldwide endorsed the Nine Points to Consider
in Licensing University Technology (the Nine Points), including the
University of California (of which UC Berkeley is a campus)122,
Harvard, and MIT.123 To encourage the further development of
licensed technologies, Point Two of the Nine Points instructs
universities to structure exclusive licenses that encourage the
development and use of licensed research tool technology.124 CRISPR
is generally thought of as a broadly applicable platform technology
rather than an research tool that enables downstream research.125
However, recently, researchers have begun exploring CRISPR as a
research tool, expanding the gene editing technology past its current
therapeutic purpose.126 With research tooling capabilities, UC
Berkeley, and Broad Institute should consider the Nine Points when
structuring CRISPR licenses.
To implement Point Two, UC Berkeley and Broad Institute
could issue narrowly drawn exclusive licenses to their surrogate
companies, allowing for broader research and development of the
human genome. 127 To be “mindful of the impact of granting overly
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broad exclusive rights,”128 UC Berkeley and Broad Institute should
limit the coverage of their exclusive licenses to select genes in the
human genome, rather than allowing surrogate companies extensive
control over all genes each institutions respective patents cover. This
will allow the surrogate companies to continue their profit-focused
research and development while encouraging a wider range of
CRISPR-Cas9 gene therapies to be developed.129
Alternatively, UC Berkeley and Broad Institute can meet Point
Two without abandoning exclusive licensing by including
performance milestones in their existing exclusive licenses.130
Providing performance milestones will encourage surrogate
companies to align with UC Berkeley and Broad Institute’s individual
development goals while preserving the surrogate-university
relationship. Milestones for CRISPR-Cas9 licenses could include
requiring surrogates to apply CRISPR-Cas9 to specific genes or
specific diseases within a reasonable timeline.
UC Berkeley and Broad Institute could also include
sublicensing requirements for surrogate companies to “address unmet
market or public health needs.”131 Currently, Caribou and Editas have
full discretion to sublicense CRISPR-Cas9 technology.132
Implementing sublicensing requirements would allow Caribou and
Editas to continue sublicensing while narrowing their discretion,
requiring sublicenses to be given for genes or diseases the surrogates
are not developing. Sublicensing requirements would not only preserve
the surrogate exclusive license model but also allow wider CRISPRCas9 application.
Another way to broaden CRISPR-Cas9 development while
continuing to grant exclusive licenses is by reserving the licensor’s
right to license within the scope of the exclusive license.133 UC
Berkeley and Broad Institute could use reserved rights to license
CRISPR-Cas9 for use in areas that the surrogate companies are not
interested in or do not have the resources to fully develop. Broad
Institute’s current “inclusive innovation” model already allows for
licenses to be given to third parties but only if the primary licensee is
not interested in pursuing the same CRISPR applications.134 With the
128
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reserved right, Broad Institute could license its CRISPR technology to
a third party without presenting the third party’s development plan to
Editas. This allows for broader application of CRISPR by multiple
companies and encourages Editas to sublicense to more third parties
because sublicensing gives them more control than licensing by Broad.
A nonexclusive license could also be an alternative to UC
Berkeley and Broad’s current overreaching exclusive licenses.
Nonexclusive licenses generally allow the licensee to use patent rights
without giving the licensee control over the enforcement or licensing
of such rights.135 This licensing scheme allows the patent owner to
grant the same rights to several parties.136 These licenses are most
commonly seen used for platform technologies with wide applications
in different fields of use.137 The application potential of CRISPR-Cas9
can be compared to such platform technologies. However, with the
additional liability risk that comes with developing genetic therapies,
nonexclusive licenses are riskier than the exclusive licenses UC
Berkeley and Broad Institute currently use.138
IV.

OPEN-SOURCE IN THE BIOTECHNOLOGY INDUSTRY

The biotechnology industry should model future licensing after
the software industry’s open-source model to “enable researchers to
improve the efficiency of research and decrease the transactions costs
involved.”139 Open-source licensing is common in software code,
which primarily relies on copyright protection.140 Although the
biotechnology industry relies on patent protections, rather than
copyright protections, open-source licensing is still a potential solution
to allow for wide access to innovative biotechnologies. In software, the
shift from “secret, copyrighted, and carefully litigated”141code to
collaboration and free distribution of source code and data allowed the
industry to accelerate development.142 An open-source approach could
similarly benefit to the biotechnology industry, helping resolve the
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patent thicket problem and anticommons dilemma previously
discussed.143
The most common open-source licenses are the General Public
License (GPL) and the Berkeley Software Distribution License
(BSD).144 GPLs are copyleft licenses that allow freedom to share and
change free software.145 The less restrictive BSD allows free use of the
BDS code if the required notices accompany the code.146 Open-source
licenses can still provide a level of secrecy. Software creators looking
to maintain secrecy can make BSD-licensed code private “since
proprietary software that includes the BSD notice can be distributed in
object code so that it may be maintained in secret.”147 Although not
entirely convertible to the biotechnology industry, open-source license
models like GPL and BSD can work as guides in creating open-source
licenses that benefit biotechnology.
There is a growing interest in the biotech industry to venture
into the world of alternative business models.148 Open-source research
and development is one alternative model that is gaining traction.
Unlike the software industry, when used in the biotechnology field,
open-source is a catch-all term to identify a scientific collaboration
business model.149 Open source promotes sharing, rather than
exclusivity, in the search for revolutionary, affordable medicine.150
With more open-source access to research and development, less
profitable disease therapies will have a better chance of gaining needed
attention. Open-source practices could result in companies placing
equal importance on medical advancement and profitability of new
drugs therapies when deciding what information to release or which
research to pursue.151
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A. Examples of Open-Source Biotechnology Research and
Development
In 2015, Pfizer discovered that its rheumatoid arthritis drug,
Enbrel, reduced the risk of Alzheimer’s by 64%.152 Rather than making
their discovery accessible to outside companies or researchers, Pfizer
buried the results.153 Pfizer claimed the results did not meet “rigorous
scientific standards” and did not want others to be led astray.154 In
reality, Pfizer took advantage of the accepted exclusivity plaguing the
biotech industry, putting profit potential over development. Pfizer’s
decision to put commercial incentives above valuable Alzheimer’s
data, positive or negative, shows how the greater biomedical industry
is disadvantaged by the rejection of open-source collaboration.155
Pfizer, UC Berkeley, Broad Institute and the larger
biotechnology community are making use of current biotechnology
practices that, unfortunately, could have disastrous consequences for
future innovation. The problem with UC Berkeley and Broad
Institute’s exclusive licenses is the inability for research to be
developed in less profitable gene therapies to begin with. Gene
applications that could benefit less profitable diseases, such as tropical
diseases that typically affect poor or developing countries, are not
enticing to large companies looking for the next “blockbuster drug.”156
This is because the commercial model Western companies operate
under only works if a drug can be sold at a price and quantity that can
cover the cost of R&D.157 This model fails with tropical diseases
because, generally, few tropical disease patients can afford to pay a
price that will recover a company’s high R&D costs.158 The
disadvantage less profitable diseases have is evident by the lack of
newly developed tropical disease drugs.159 It is estimated that only
around 1% of newly developed drugs are for tropical diseases, such as
African sleeping sickness, dengue fever, and leishmaniasis.160
Fortunately, the biomedical industry may be pushed into
accepting open-source research and development in the near future.
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The recent global pandemic has assisted in accelerating open-source
collaboration. Thanks to Chinese researchers openly publishing the
COVID-19 genetic sequence, pharmaceutical companies and
researchers were able to find existing drugs that have been repurposed
to fight the virus and develop new vaccines quickly.161 The COVID19 pandemic is an incredible example of how open-source can benefit
companies’ profits and public’s health. Advocates for open-source are
hoping that the pandemic’s “open-source model can be replicated to
address other challenges in biomedical research.” 162
Even before the pandemic, some pharmaceutical companies
were slowly moving toward open-source development. Offering a
company’s intellectual property to the public risks losing out on profits
and credit, but diseases that affect poor populations, like tropical
diseases, do not provide large profits to begin with.163 Tropical diseases
impact roughly one-sixths of the worlds population,164 yet
pharmaceutical companies devote little time and resources toward
cures because such diseases lack economic incentives.165 Tropical
diseases are less commercially attractive because they take resources
away from the research and development of “profitable” diseases that
affect countries with rich populations willing and able to pay
“blockbuster” drug prices.166
The Tropical Disease Initiative (TDI) is a web-based opensource drug development project tapping into the underdeveloped and
less profitable tropical disease market.167 Collaboration between
researchers from laboratories, universities, institutes, and corporations
work together to explore under-researched tropical diseases benefiting
populations traditionally ignored by the biomedical industry.168
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Similarly, the Medicines for Malaria Venture (MMV),
working toward new Malaria treatments, shipped hundreds of its
Malaria Boxes to 200 researchers in 30 countries.169 The compounds
in the Malaria Box that were used by one researcher “identified
promising compounds that attacked the Plasmodium falciparum
malaria parasite [leading] to further drug development work.”170 The
same researcher even found compounds active against parasites
unrelated to Malaria that could protect against a parasite that causes
childhood blindness. 171 The Malaria Box and MMV’s other projects,
the Pathogen Box and the Pandemic Response Box, show a realistic
open-source research model.172 These boxes show the move from
commercial drug research and development toward a collaborative
model where intellectual property is shared instead of guarded.
MMV also collaborated with GlaxoSmithKline and St. Jude
Children’s Research Hospital to create a list of 20,000 potential
antimalarials now logged in an open chemical database curated by the
European Bioinformatics Institute.173 Open-Source Pharma
Foundation, founded in 2018, is also an open-source “success story.”
In 2019, the OSPF team took a generic diabetes drug into “Phase 2B
clinical trials as a tuberculosis treatment.”174 Typically a new drug
would cost $500 million to develop,175 but OSPF’s tuberculosis
treatment required under $50,000 and took less than a year to develop,
showing the cost and time efficiency of collaborative research.176
B. The Biotechnology Industry’s Hesitation Toward OpenSource
Understanding why open-source was widely accepted in the
software industry can help address the hesitation to adopt similar
practices in other industries.177 In the early stages of the industry,
software was the “Wild West of the legal world.”178 The unknown of
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the industry allowed open-source to flourish, largely due to the
inability of legislators, regulators, and policy-makers to comprehend
the new software frontier.179
Generally, the more reliant a field is on vested intellectual
property interests, “the more resistant that field will be to the idea of
open-source models.”180 Relying heavily on already existing and wellregulated intellectual property protection, the biotechnology industry’s
ability to explore new methods of sharing information and
collaborating is limited. Open-source systems utilized by the software
industry are not directly transferable to biotechnology.181 The notable
differences between software and biotechnology create an exciting
opportunity to customize open-source projects to fit specific
biotechnology research.182
Moving from tightly held secrets to open access is a radical
idea for many companies. The Biological Innovation for Open Society
(BiOS) initiative, created in 2005, is an open-source biological
technologies project looking to promote open-source development in
biotechnology, create new legal mechanisms to protect open-source
developments, and provide intellectual property analysis to protect
against patent liability.183 BiOS is working to accelerate companies’
open-source acceptance, with protections specific to biotechnology.184
Projects like BiOS and other open-source research companies
receiving public recognition provide promise for the biotechnology
industry moving toward more open-source collaboration.
Critics of open-source research fear that the lack of standards
within an open-source process will deteriorate the quality of future
scientific findings.185 This fear is unfounded given that open-source
projects are not only constantly “peer-reviewed” but also continuously
“peer improved”.186 With additional quality safeguards such as
industry-developed Good Manufacturing Practices, Good Laboratory
Practices, and Good Clinical Practices the fear of lackluster research
and discovery becomes even less credible.187
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C. Benefits to Open-Source in the Biotechnology Industry
Benefits to an open-source model include the elimination of
errors in research. Open access to research and findings “encourages
an open, critical discussion in order to foster higher quality
research.”188 Increased accessibility also allows for maximal earlystage development.189 Receiving outside input during the early
research phases, rather than after the initial discovery, will benefit the
efficiency of the research and potentially cut down on research costs.
190
Open databases and access to new research tools or promising
therapeutics could allow neglected diseases to be properly studied.191
Cutting back on cost will lead to better research for diseases and
treatments affecting poor populations and developing nations.192
Further economic benefits to implementing open-source in the
biotechnology industry include reduced duplicate research.193
Transparency cuts down excessive costs where research being perused
by one has already been studied by another.194 Fear of profit loss in an
open-source model is mitigated by making up profits that would have
been generated through complementary goods and services.195
Providing public access to technology and research companies can also
boost their reputation as being innovative and socially conscious.196
Interest from the public could also lead to volunteer labor, further
cutting down the cost of research.197 Overall, open-source promises
thorough review, revision, and modification by combining the knowhow from a wide pool of interested parties.198
CONCLUSION
In the past few years, CRISPR-Cas9 has developed a reputation as
the future of gene editing, becoming a mainstream gene-editing
technology. During this time, UC Berkeley and Broad Institute have
established themselves as pioneers in the CRISPR-Cas9 industry. With
court judgments and esteemed awards, UC Berkeley and Broad
Institute have legitimate evidence to establish ownership of their
188
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respective intellectual property, were they to be misused or stolen. The
extensive legal battle between the two institutions found Broad
Institute the “victor,” legitimizing its claim to its extensive CRISPRCas9 patent portfolio.199 This past year, UC Berkeley has also
solidified its place as a CRISPR pioneer, with the university’s
biochemist, Jennifer Doudna, receiving the 2020 Nobel Prize in
Chemistry200 for developing CRISPR-Cas9.201 This recognition makes
both institutions’ ability to provide open-source access to select
CRISPR-Cas9 gene applications possible and realistic, as it is evident
that CRISPR-Cas9 therapy or treatment will have been a product of
UC Berkeley or Broad Institute’s intellectual property.
The CRISPR industry is still relatively new, being first discovered
in 2012.202 Understandably, universities wish to keep intellectual
property rights protected by licensing to surrogate companies. This
surrogate licensing system gives universities more control over how
their CRISPR-Cas9 technology is being used, while mitigating the risk
associated with IP licensing. However, the current surrogate model
used by the leaders of the CRISPR-Cas9 industry heavily restricts
access to this revolutionary technology. Exclusive licenses are a
common practice in biotechnology and should not be completely
discarded from the universities’ intellectual property rights toolkit.
However, while licenses are an important tool for protecting
intellectual property, universities must change their current exclusive
license system to allow more than just a handful of companies access
to CRISPR-Cas9.
While countless alternatives to exclusive licensing exist, opensource collaboration provides numerous benefits and has already
gained popularity as a useful tool in COVID19 research. Open-source
should not eliminate licensing altogether. The open-source method is
not a threat to the blockbuster drug development model, which is
currently the standard in the biomedical industry.203 Companies can
continue to use patents to protect the most commercially promising
199
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intellectual property, while open-source collaboration can fill in the
gaps of less profitable but still vital, research and development.
UC Berkeley and Broad Institute’s extensive CRISPR-Cas9 patent
portfolios could benefit from allowing selective open-source access.
To suggest these institutions completely give up their intellectual
property rights over CRISPR-Cas9 application would be naive.
However, ignoring the move toward collaboration within the
biotechnology field is also naive. UC Berkeley and Broad Institute
should limit their exclusive licenses to select gene applications and
allow open-source access to less profitable genes that otherwise may
go ignored or unexplored otherwise. Broader access to CRISPR-Cas9
intellectual property is in the best interest of the patent owner and the
greater public because it encourages innovation, breeds healthy
competition, and allows for CRISPR technology to be applied to a
larger range of the human genome.

